Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study-Reference-Cited by-同舟云学术

Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study

Published:2018-12-14 Issue:2 Volume:36 Page:462-477
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Kamar Nassim,Cassuto Elisabeth,Piotti Giovanni,Govoni Mirco,Ciurlia Giorgia,Geraci Silvia,Poli Gianluigi,Nicolini Gabriele,Mariat Christophe,Essig Marie,Malvezzi Paolo,Le Meur Yannick,Garrigue Valerie,Del Bello Arnaud,Rostaing Lionel

Funder

Chiesi Farmaceutici S.p.A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s12325-018-0855-1/fulltext.html

Reference31 articles.

1. Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, et al. OPTN/SRTR 2016 annual data report: kidney. Am J Transplant. 2018;18(Suppl 1):18–113.

2. Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.

3. Food and Drug Administration. Draft guidance on tacrolimus june 2016.